医学记录中中轴型脊柱关节炎疾病活动度结局指标的报告对生物治疗留存率的影响:法国日常实践中司库奇尤单抗使用的范例
该回顾性多中心研究评估了法国日常实践中906例中轴型脊柱关节炎患者报告推荐复合指数(BASDAI+C反应蛋白或ASDAS)的频率及其对司库奇尤单抗留存率的影响。仅22%的患者报告了至少一种推荐复合指数;优化报告者的1、2、3年留存率均更高(分别为64% vs 57%、55% vs 41%、52% vs 38%,log rank检验p=0.016),且停药风险更低(HR 0.70,95%CI 0.5至0.88,Cox模型p=0.003)。
要点
- 日常实践中仅22%的axSpA患者报告了推荐复合指数。
- 优化报告者司库奇尤单抗留存率更高,停药风险更低(HR 0.70)。
- 该研究提示报告推荐复合指数可能与更高的生物治疗留存率相关。
核心结论
- 该研究提示报告推荐复合指数用于监测axSpA可能与更高的生物治疗留存率相关。
研究设计与样本
- 回顾性多中心研究,纳入906例中轴型脊柱关节炎患者,评估司库奇尤单抗起始时及随访第一年至少一次报告推荐复合指数(BASDAI+C反应蛋白或ASDAS)的情况。
主要发现
- 906例入组axSpA患者中,22%报告了推荐复合指数。
- 优化报告组vs未优化报告组随访1年留存率64%(57-71)vs 57%(54-61),2年55%(48-62)vs 41%(38-45),3年52%(44-59)vs 38%(34-42),log rank检验p=0.016。
- 优化报告组司库奇尤单抗停药风险更低(HR 0.70,95%CI 0.5至0.88,Cox模型p=0.003)。
关键数值与推荐
- 推荐复合指数定义为BASDAI+C反应蛋白或ASDAS,在司库奇尤单抗起始时及随访第一年至少一次报告。
- 优化报告组vs未优化报告组随访1年留存率64%(57-71)vs 57%(54-61),2年55%(48-62)vs 41%(38-45),3年52%(44-59)vs 38%(34-42),log rank检验p=0.016。
- 优化报告组vs未优化报告组停药风险HR 0.70(95%CI 0.5至0.88),Cox模型p=0.003。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the frequency of reporting composite indices evaluating axial spondyloarthritis (axSpA) disease activity in daily practice and to assess its impact on the secukinumab (SEC) retention rate. METHODS: Study design: Retrospective, multicentre. DATA COLLECTED: (1) Recommended composite indices: Bath Ankylosing Spondyltitis Disease Activity Index (BASDAI) +C reactive protein or Ankylosing Spondylitis Disease Activity Score (ASDAS) at the time of initiation of SEC and at least once during the first year of follow-up; (2) Drug retention rate: percentage of patients still on SEC over time according to whether at least one recommended composite index had been optimally reported. RESULTS: A recommended composite index has been collected in 22% of the 906 enrolled axSpA patients. The percentage of patients still on treatment after 1, 2 and 3 years of follow-up was greater in those for whom at least one composite index had been optimally reported (respectively, 64% (57-71) vs 57% (54-61), 55% (48-62) vs 41% (38-45) and 52% (44-59) vs 38% (34-42), log rank test, p=0.016) with a lower risk of SEC discontinuation for these patients (HR: 0.70 (95% CI 0.5 to 0.88), Cox model, p=0.003). CONCLUSION: This study suggests that reporting of recommended composites indices for monitoring axSpA might be associated with higher retention rates of biological therapies.
引用
- Dougados M, Lucas J, Desfleurs E, et al. Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France. RMD Open. 2022. PMID: 35301266. doi:10.1136/rmdopen-2021-002106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。